Skip to content
OpenCapital
Get started

Gilead Sciences GILD Intangible assets — net

Intangible assets — net at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
——
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
——
CG Oncology logo
CG OncologyCGON
——
Biogen logo
BiogenBIIB
——
AbbVie logo
AbbVieABBV
——

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$155.39B+23.8%
Enterprise value$169.94B+19.7%
P/E16.9×-4.2×
P/S5.2×+0.9×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's intangible assets — net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's intangible assets — net?
Gilead Sciences (GILD) reported intangible assets — net of $14.08B in Q1 2026.
How has Gilead Sciences's intangible assets — net changed year-over-year?
Gilead Sciences's intangible assets — net decreased by 14.5% year-over-year, from $16.47B to $14.08B.
What is the long-term trend for Gilead Sciences's intangible assets — net?
Over 5 years (2020 to 2025), Gilead Sciences's intangible assets — net has grown at a -2.0% compound annual growth rate (CAGR), from $16.24B to $14.68B.